Feds may need $7B to adequately respond to monkeypox outbreak - WaPo

Jul. 26, 2022 5:46 PM ETEmergent BioSolutions Inc. (EBS), SIGA, BVNKF, CMRXBy: Jonathan Block, SA News Editor36 Comments

Monkeypox pandemic concept: dice surrounded by syringes and vials make up the word monkeypox

Cristian Storto Fotografia/iStock via Getty Images

  • The Biden administration may require as much as $7B in order to deal with the current monkeypox outbreak in the country, according to a memo obtained by The Washington Post.
  • The money would be used for monkeypox vaccines, treatments, and testing. It would also allow HHS to support monkeypox vaccine manufacturing in the U.S. Bavarian Nordic's (OTCPK:BVNKF) JYNNEOS shot is made in Denmark.
  • The newspaper reported that White House aides recently brought up options on how to respond to monkeypox with Democrats on the Senate Committee on Health, Education, Labor & Pensions. However, a formal request for funding has yet to be made.
  • The memo also calls for as much as $31B in additional funding to fight COVID-19.
  • Monkeypox names: SIGA Technologies (NASDAQ:SIGA), Chimerix (NASDAQ:CMRX), and Emergent Biosolutions (NYSE:EBS).
  • Bavarian Nordic is in discussions to boost production of JYNNEOS.

Recommended For You

Comments (36)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.